Unicar-Therapy
Unicar-Therapy is a China-based cell therapy company that leads 2 cancer trials in OnCo, testing the CAR-T products U16 and U32 in non-Hodgkin lymphoma and acute myeloid leukaemia.
Overview
Unicar-Therapy is a Shanghai CAR-T developer founded in 2015 that builds its own cell therapy products on in-house platforms with integrated manufacturing. Its registered pipeline covers blood cancers and solid tumours. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT05768529 (phase 1/2, Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma) and NCT07036250 (phase 1/2, Clinical Study of U32 in Patients With Acute Myeloid Leukemia). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
not linked directly; found by shared links- TrialAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Shares Non-Hodgkin lymphoma (all types), Acute myeloid leukaemia.
- TrialTGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shares Non-Hodgkin lymphoma (all types), Acute myeloid leukaemia.
- TrialStudy of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Shares Non-Hodgkin lymphoma (all types), Acute myeloid leukaemia.
- TrialSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Shares Non-Hodgkin lymphoma (all types), Acute myeloid leukaemia.
- TechnologyFlow cytometers
Shares Non-Hodgkin lymphoma (all types), Acute myeloid leukaemia.